Cop
yright
© AE&M all rights r
eser
ved.
Glycated albumin: a potential
biomarker in diabetes
Priscila Aparecida Correa Freitas1,
Lethicia Rozales Ehlert¹, Joíza Lins Camargo1,2
ABSTRACT
Diabetes mellitus (DM) is a chronic and metabolic disease that presents a high global incidence. Glycated hemoglobin (A1C) is the reference test for long-term glucose monitoring, and it exhibits an association with diabetic chronic complications. However, A1C is not recommended in clinical situations which may interfere with the metabolism of hemoglobin, such as in hemolytic, secondary or iron deficiency anemia, hemoglobinopathies, pregnancy, and uremia. The glycated albumin (GA) is a test that reflects short-term glycemia and is not influenced by situations that falsely alter A1C levels. GA is the higher glycated portion of fructosamine. It is measured by a standardized enzymatic methodology, easy and fast to perform. These laboratory characteristics have ensured the highlight of GA in studies from the last decade, as a marker of monitoring and screening for DM, as well as a predictor of long-term outcomes of the disease. The aim of this review was to discuss the physiologi-cal and biochemistry characteristics of the GA, as well as its cliniphysiologi-cal utility in DM. Arch Endocrinol Metab. 2017;61(3):296-304.
Keywords
Diabetes mellitus; glycated albumin; glycated proteins 1 Programa de Pós-graduação
em Ciências Médicas – Endocrinologia, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brasil 2 Serviço de Endocrinologia, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brasil Correspondence to:
Joíza Lins Camargo Serviço de Endocrinologia, Hospital de Clínicas de Porto Alegre Rua Ramiro Barcellos, 2350 Prédio 12, CPE, 4º andar 90035-903 – Porto Alegre, RS, Brasil jcamargo@hcpa.edu.br
Received on Aug/2/2016 Accepted on Feb/13/2017 DOI: 10.1590/2359-3997000000272
INTRODUCTION
D
iabetes mellitus (DM) is a chronic metabolicdisease caused by diminished or absent secretion of insulin or even by reduced tissue sensitivity to insulin (1,2). Presently, DM is a worldwide epidemic and a great challenge to health care systems everywhere. The International Diabetes Federation (IDF) estimates that one in eleven adults have DM, totalizing approximately 415 million people, and 193 million of them have not yet been diagnosed (1).
Chronic hyperglycemia is a common feature in all subtypes of this disease and is associated with long-term damage, which increases the morbidity and mortality rates and causes dysfunction of different organs, such as kidney failure, blindness, and amputation of limbs (2). These chronic complications are costly to the health care systems and reduce the life expectancy of diabetic patients (1,2).
Currently, the laboratory tests used to diagnose DM are glycated hemoglobin (A1C), fasting plasma glucose (FG) and two-hour plasma glucose (2hG) after a 75g oral glucose tolerance test (OGTT) (2,3). A1C is also the reference test for glycemic monitoring since it directly reflects mean glycemia (5) and is strongly
correlated to the long-term complications of DM (4,5). However, the use of A1C is not recommended in some clinical situations that influence the hemoglobin metabolism (3,6,7), due to the possible interference in its results making them misinterpreted. Moreover, recent studies have shown a disagreement between the A1C levels in different ethnic groups for equal levels of glycemia (8,9), but the reasons for these disparities have not yet been well explained.
Glycated albumin (GA) is a laboratory test that has gained some importance for glycemic monitoring in DM in the last decades (10,11). GA is one of the fructosamines, but it has the advantage of not being influenced by the concentration of other serum proteins since it is specific to the albumin glycation rates (12). Further, GA does not require fasting for its measurement and reflects short-term glycemia due to the half life time of the albumin, which is approximately 3 weeks. Compared to A1C, GA is not affected by the presence of hemolytic processes and abnormal Hb (13). Besides, in conditions such as anemia, pregnancy, postprandial hyperglycemia and DM using insulin, GA seems to be a better glycemic marker than A1C (11) and also it is especially indicated for diabetic patients on
Cop
yright
© AE&M all rights r
eser
ved.
hemodialysis (14,15). Recently, studies on type 1 (16) and type 2 DM patients (17) reported an association of GA with the chronic complications of the disease.
Although GA is being studied in the last few years, this test is not yet widely used in laboratory routine, and few commercial reagents are available on the market to its analysis. However, the results of clinical investigations make GA a promising marker in DM. In this context, the proposal of this review is to present the physiological and laboratory characteristics of GA, and discuss its clinical usefulness in the diagnosis and management of DM.
BIOCHEMICAL CHARACTERISTICS OF GA AND
BIOLOGICAL IMPACT OF GLYCATION
Albumin is a high molecular weight protein with 66.7 kDa, composed of a single polypeptide chain which contains 585 amino acids, 17 disulfide bridges and 3 homologous domains that are connected in a helical structure (18). It is the main plasma protein, representing about 60% of the total proteins in the blood, with concentrations between 3.0 and 5.0 g/dL and a half-life of 14 to 20 days (18,19). Albumin structure makes it easier to perform its physiological functions, such as maintaining pH and blood osmotic pressure. Also, albumin acts as a powerful antioxidant and as the main transporter of metabolic products, ions, nutrients, drugs, hormones and fatty acids (20).
Similar to the other proteins, albumin also goes through the physiologic process of glycation (21). By definition, glycation is a non-enzymatic spontaneous reaction in which a reducing sugar is added to a free amino group, typically lysine or arginine present within proteins, also called as Maillard reaction (Figure 1) (18-20). The first step of this reaction involves the formation of an unstable and reversible product known as Schiff base, formed by the bonding of a carbonyl group of an acyclic carbohydrate with the N-terminal amino acid (19). This intermediate product can suffer a change in its conformation and result in a stable and irreversible ketamine, known as the Amadori product (22). The main Amadori adduct formed is fructoselysine, a reaction between glucose and lysine, which may occur on 59 lysine sites present in albumin (18). However, lysine 525 has been identified as the largest albumin glycation site, which is evidenced both
in vivo and in vitro experiments (23,24). The set of
ketamines formed by non-enzymatic glycation of
proteins is chemically called “fructosamine”. Among the serum fructosamines, GA is the main constituent, representing about 80% of the total of glycations in plasma (18).
The glucose concentration and time of exposure between protein and sugar are the determining factors for the glycations performed during the life of the protein. In other words, glycation depends on the degree and duration of hyperglycemia (22). Extracellular proteins, such as albumin, may be more susceptible to Amadori rearrangements than intracellular proteins as Hb (18). This is due to plasmatic proteins being directly exposed to plasma glucose. These features could justify the differences in the rates of albumin glycation that are about 9 to 10 times greater than those of hemoglobin (25). However, in the in vitro experiment by Ueda and Matsumoto, it was evidenced that GA production was about 4.5 times greater than A1C after adding known and equal concentrations of glucose in previously treated samples from healthy volunteers. These findings showed that even in identical in vitro glycation conditions, GA is produced faster than A1C (20).
In advanced glycation stages, additional oxidative and irreversible events occur regarding the glycated proteins, producing stable and heterogeneous compounds known as advanced glycation end products (AGEs – Figure 1). Although the formation of AGEs
NH2 NH2 NH2 + + Shiff base Advanced glycation end products (AGEs) Reducing sugar Reducing sugar Reducing sugar Protein Protein Protein Reactive dicarbonyl compounds Amadori product
Figure 1. Maillard reaction illustration. In the first glycation stage, there is
production of Shiff base by a reaction between a reducing sugar and a free amine group present into the polypeptide chain of plasma proteins and, subsequently, a rearrangement yield the Amadori product. In the following stages, the degradation of the Shiff base and Amadori products, as well as sugar autoxidation are responsible for forming reactive dicarbonyl compounds, known as AGEs’ precursors.
Cop
yright
© AE&M all rights r
eser
ved.
is a normal process, conditions of typical hyperglycemia in patients with DM increase their production rates (26). AGEs receptors are present in cells of different tissues, such as macrophages, muscle, endothelial and glial cells (27). They are expressed as membrane molecules, constituents of immunoglobulin superfamily and act as signal transduction receptors, inducing oxidative stress and starting an inflammatory cascade by activation of the nuclear factor-κB (NF-κB). NF-κB modulates the gene transcription of pro-inflammatory molecules such as interleukins 1, 6 and 8 and tumor necrosis factor-α, and also the vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 (26). As a consequence of this cascade, there is an increased production of reactive oxygen species, which is directly associated with the pathogenesis and long-term complications in DM (21,27). Kisugi and cols. evaluated samples from a patient with DM during one month of hospitalization due to hyperglycemia symptoms and evidenced that the formation of AGEs was drastically reduced with the concomitant reduction of the GA levels (24).
LABORATORY MEASUREMENT OF GA
Historically, fructosamine has been used in clinical practice when a short-term glycemia evaluation is needed (12,28). However, this test presents low accuracy since it is influenced by all plasma proteins and also by other molecules present in the blood, such as bilirubin, uric acid and low molecular weight substances (12). Further, fructosamine is not available at all laboratories (18,29) and there are no well-established international standards for its use.
Methods for the evaluation of GA have been developed since the 1980s using serum or plasma samples (28). The older methods presented many disadvantages due to the techniques complexity or the high costs and/or lack of precision. Besides, the non-standardization of these assays corroborated to the unpopularity of GA, and all attention were directed to A1C (30).
GA can be measured by ion-exchange high-performance liquid chromatography (HPLC), boronate affinity chromatography, immunoassays (radioimmunoassay and Enzyme Linked Immuno Sorbent Assay), colorimetric method with thiobarbituric acid and enzymatic methods using proteinase and ketamine oxidase (12,28,29,31), however these
methods are currently not available in the laboratory routine (32).
The reference intervals described for GA depend on the method used since GA levels may vary according to the glycation sites analyzed by the assay employed, and also if the method of analysis considers the GA molecule for measurement and not its glycated amino acids (31). For instance, the immunoassay techniques, colorimetric methods with thiobarbituric acid and enzymatic methods consider the glycated amino acids as the reference for the GA levels. On the other hand, the HPLC techniques and other chromatography methods consider the GA molecule to define their levels. Despite this difference, all methods available agree that the proportion of GA in patients with DM increases 2 to 5 fold compared to normoglycemic patients (18).
An enzymatic methodology with a shorter operational time and easier to perform both manually and automatically was proposed to evaluate the GA levels in order to overcome the limitations of the previously existing techniques (12). This method presents three steps (Figure 2), using specific proteinase for albumin and ketamine oxidase, besides the bromocresol green reagent for albumin determination and later calculation of %GA. In the validation performed to introduce the test on the market, the analytic performance was excellent and the assay was not influenced by bilirubin and glucose, but a slight interference in the GA levels in the presence of Hb and ascorbic acid was reported (12). Other studies described similar results, concluding that the new enzymatic methodology, known as “Lucica
GA-L®” (Asahi Kasei Pharma Corporation, Tokyo,
Japan) showed reproducibility, accuracy (31) and a good correlation with A1C (30). Subsequently, other manufacturers have released similarly methodologies for GA analysis, but instead of a specific measurement of its levels, these assays employ math equations to obtain %GA levels (33,34). In addition, the biological
variation of GA measured by Lucica GA-L® is lower
when compared to fructosamine and A1C (1.7%, 2.8% and, 2.4%, respectively) (35).
GA presents good stability when frozen at very low temperatures. In the study by Kohzuma and cols. frozen samples at -80ºC maintained the GA levels stable for 4 years (31). Watano and cols. found similar results for storage of serum samples at -70ºC. However, they observed a considerable increase in GA levels frozen at -20°C after 6 months (36). Nathan and cols. measured the GA levels in samples of participants
Cop
yright
© AE&M all rights r
eser
ved.
in the study The Diabetes Control and Complications Trial Research Group (DCCT) frozen at -70ºC 23 years ago and concluded that the stability of this analyte remained adequate (16).
However, despite all the characteristics cited, the GA test is not yet regularly available in laboratory practice (3), but it has been much used in DM clinical research in the last decade. The factor responsible for the increased number of studies on GA was the consolidation, although without a defined international
consensus, of Lucica GA-L® enzymatic assay for GA
determination. Even though others enzymatic assays for GA have been launched into the market, currently there are only foreign suppliers available (34). It makes the GA a costlier test than A1C in Brazil. Recently, we compared two different assays for GA and the price per test was around U$ 4 to 6, in contrast with A1C test that is around U$ 2 to 3 in Brazil (34). However, this outlook is likely to change in a near future.
USE OF GA UNDER CONDITIONS THAT AFFECT A1C
In clinical practice, A1C is used as a reference test for glucose monitoring in DM, and it is also a diagnostic tool (2). However, there are some punctual disadvantages and
controversies that limit it use. They are related to certain clinical situations or to the analytical methods employed (3,6). These conditions may yield false results for A1C that are not truly correlated with the mean glycemia (28), and directly affecting the identification and management of patients with DM. In such cases, GA may be an adequate alternative for A1C in the glycemic control (37).
GA and presence of alterations in Hb
GA can be used as an alternative to A1C in any hematological alteration that interferes in the half-life of red blood cells and/or in the structure or chemical characteristics of Hb (28). Hemolytic anemias and bleeding episodes reduce the A1C values, while iron deficiency anemias, thalassemias, and hemoglobinopathies may elevate its results (6,11,38). During the fetal period, the main type of Hb in the red blood cells is the fetal Hb (HbF), which is gradually replaced by HbA after birth. Since A1C is a glycation product of the HbA, neonates tend to have falsely diminished levels (39). However, the interferences with A1C measurements are method-dependent. Some analytical methodologies may not be affected by common interferences such as hemoglobin variants. The National Glycohemoglobin Standardization Program
Figure 2. Enzymatic reaction for GA determination. First step: glycated amino acids are released from the GA molecule through an albumin-specific
protease. A ketoamine oxidase separates the free amino acids and glucosone, this last an intermediate product of Amadori reaction. The final pigment is proportional to the amount of GA in the sample; Second step: plasma albumin reacts with bromocresol green into an acid environment, resulting in a colored compound that is related to total albumin concentration; Third step: the percentage of GA is obtained by a math calculation considering the two previous reactions. First step Second step Third step Total albumin Bromocresol green
GA% = Glycated albumin X 100
H2O + O2 H2O2 + chromogem
Total albumin Ketoamine oxidase Glycated amino acids OH HO Br Br Br Br O O O S Glycated albumin Protease Peroxidase Pigment Pigment Amino acids + Glucosone
Cop
yright
© AE&M all rights r
eser
ved.
(NGSP) provides detailed information regarding interference in A1C assays by manufacturers (7).
GA and pregnancy
During pregnancy, it is recommended that women who already have DM and those who develop gestational DM be followed by glucose self-monitoring and by the A1C levels (2). However, it has been well established that during the last months of pregnancy there is an increased demand for iron, which directly reflects on changes in the A1C throughout the pregnancy (40). In a prospective study by Hashimoto and cols. conducted in pregnant Japanese women with DM, a significant elevation of A1C was found at the end of pregnancy, inversely to the ferritin levels and transferrin saturation. On the other hand, GA remained stable through this period, because it did not suffer interference from the physiological changes characteristic of pregnancy (41).
GA and chronic kidney disease (CKD)
In patients with DM and CKD, A1C may not be a reliable marker of glycemic control (42). Patients with CKD generally present erythropoietin deficiency and, consequently, they develop anemia. Thus it is necessary to use exogenous erythropoietin to compensate the diminished endogenous synthesis by the kidney, and also iron, which falsely alters the levels of A1C. Further, these patients may need blood transfusion frequently and, when on hemodialysis, they present a 20-50% diminished lifetime of the erythrocytes, also contributing to false values of A1C (43). The increased uremia in CKD results in the production of carbamylated Hb, an in vitro interfering factor in some analytic methodologies for A1C (6).
Some studies have demonstrated that GA provides a more precise control of glycemia in patients with
advanced stages of CKD (14,15,42). However, in the presence of massive proteinuria with diminished serum albumin, the GA levels can also be falsely altered (42,44), and it is necessary to perform a critical evaluation and adequately choose the best glycemic marker in this condition.
GA IN THE DIAGNOSIS OF DM
Despite the evident informative value of A1C in monitoring DM, some authors have questioned the cutoff point used for this test in diagnosing the disease. This is because the current criteria adopted show a discrepancy between the proportion and profile of patients identified as having DM by the A1C, compared to the tests based on glycemia (45,46). In addition, the patients who present special conditions that interfere with A1C results should be screened for DM with alternative markers. Since the enzymatic method for GA was recently developed, few diagnostic accuracy studies of GA for DM have been published (Table 1).
In 2006, the Japan Diabetes Society (JDS) established a reference interval for GA from 12.3% to 16.9% (47). Years later, in a larger study (N = 1.575), Furusyo and cols. published a reference interval for GA from 12.2% to 16.5%, corroborating with that reported by the JDS. Further, this study found that the cutoff point of GA ≥ 15.5% presented a good sensitivity and specificity (both 83.3%) to identify DM, using FG and/or A1C (≥ 126 mg/dL and ≥ 6.5%, respectively) as reference tests (48). In 2015, the same group evaluated 176 residents of Japan diagnosed with DM by the OGTT, according to WHO criteria. ROC curve analysis showed that GA presented significant differences in the area under the curve (AUC) for DM diagnosis, and these values increased when combining GA with FG or 2hG than GA when isolated (AUC: 0.863, 0.968 and 0.672, respectively) (49).
Table 1. Diagnostic accuracy studies of GA and the cutoff points found to screening DM
Study N Country Male RI GA (%) DM cutoff SxS
Tominaga and cols. 2006 699 Japan 52% 12.3 - 16.9 -
-Paroni and cols. 2007 32 Italy 37% 11.7 - 16.9 -
-Kohzuma and cols. 2011 201 USA 47% 11.9 - 15.8 -
-Furusyo and cols. 2011 1.575 Japan 30% 12.2 - 16.5 15.5% 83.3 x 83.3
Hwang and cols. 2014 852 Korean 58% - 14.3% 66.4 x 52.5
Ikezaki and cols. 2015 176 Japan 46% - 15.2% 62.1 x 61.9
Hsu and cols. 2015 2.192 Taiwan 50% - 14.9% 78.5 x 80.0
Testa and cols. 2017 252 Italy 38% 9.0 - 16.0 -
Cop
yright
© AE&M all rights r
eser
ved.
Hwang and cols. assessed different cutoff points of GA for DM and pre-DM diagnosis in 852 Korean adults, using the ADA criteria to classify the disease. The study reported a cutoff point of 12.5% for pre-DM and 14.3% for DM. GA presented greater sensitivity than A1C (66.4% GA versus 52.5% A1C), but less specificity (88.3% GA versus 95.1% A1C) to predict 2 hG ≥ 200 mg/dL. When the values of 14.3% of GA were associated with FG ≥ 126 mg/dL, higher sensitivity was obtained (77.5%, CI: 72.17–82.0) to diagnose DM (50). Hsu and cols. described a cutoff point of GA ≥ 14.9% for DM (sensitivity: 78.5%; specificity: 80.0%), evaluating 2,192 adult individuals in Taiwan. Also, when the values of 5.7% and 6.5% of A1C were considered, the corresponding GA was 14.5% and 16.5%, respectively (51).
Smaller studies described GA intervals in individuals without DM ranging from 11.9 to 15.8% (N = 201 residents of North Carolina, USA) (31); 10.2 to 16.1% (N = 217 African immigrants in America) (52); 10.5 to 17.5% (N = 44 volunteers of a Canadian study) (33); and 9.0 to 16.0% (N = 252 European persons) (53). In young obese persons aged from 10 to 18 years, the value of GA to diagnose DM was ≥ 12% when 2 hG was used as the reference test, and ≥ 14% when A1C was used as reference diagnostic criterion (54).
GA IN GLUCOSE MONITORING
Differently from A1C long-term formation (about 120 days, mean life of the erythrocytes), GA is formed in a period of approximately 2 to 4 weeks (Figure 3) (37). This feature enhances GA sensitivity to the rapid alterations in glucose levels, which may not be efficiently identified with an isolated measure of plasma glucose (13,19).
Compared to A1C, GA is more suitable to monitor the beginning of drug therapy in DM (55), and also to control the dose and change of medication (51), since its levels diminish faster than A1C in intensive treatment (19). Paroni and cols. evidenced that GA was a better marker to evaluate the responses to treatment with insulin in type 2 DM patients with inadequate glycemic control, and also that GA presented a greater correlation with FG than A1C (R = 0.75 versus R = 0.54, respectively) (30). Moreover, Yoon and cols. reported that the worsening of the beta-pancreatic cell function was associated with the time of duration of DM, and also with increased GA and GA/A1C ratio, but not with A1C alone (56).
In general, GA can be employed to show mean glycemia and also to evaluate the glycemic variability and postprandial glucose levels more adequately than A1C (37,57). Elevations in postprandial glycemia are associated with the increased risk of cardiovascular diseases and microangiopathy, thus the detection of these glucose variations is important (37). The reasons why GA is better related to postprandial glycemia have not yet been elucidated (11).
GA AS A PREDICTOR OF LONG TERM
COMPLICATION IN DM
The chronic hyperglycemia considerably increases the risk of developing micro and macrovascular diseases over time (1,2). A1C is a marker that has been strongly explored in clinical research and much evidence has supported its use as a predictor for these complications in DM (4,5). However, there is still controversy if mean glycemia itself or glycemic variability is the main determining factor for chronic damage in DM (16). Recent studies have evaluated the predictive potential value of tests that are more associated with the short term glycemia and that can be used as alternative markers for A1C, such as GA (8,16,17,58).
Selvin and cols. cross-sectionally evaluated 1,600 individuals recruited for the Atherosclerosis Risk in Communities (ARIC) study conducted in the USA. They observed that in participants with type 2 DM, both GA and fructosamine were significantly associated with the prevalence of albuminuria, CKD, and retinopathy (8). In a longitudinal study, the same group evaluated 12,306 participants from ARIC, who were followed for over 20 years and demonstrated that both GA and fructosamine were similarly associated with A1C to predict retinopathy and CKD in DM. These findings were confirmed in
Figure 3. Glycation rates of GA e A1C. GA is produced over the life span of
albumin of approximately 8 weeks, however, the first 2 weeks account for half of its production. Differently, due to the life span of erythrocytes, that is around 120 days, A1C takes approximately 4 months to be completely produced, and the first month is responsible for half of its glycation.
0 15 GA A1c 30 60 25% 25% 25% 25% 50% 50% 90 120 days
Cop
yright
© AE&M all rights r
eser
ved.
patients diagnosed with DM during the baseline period and in those who developed DM during the follow-up. The odds ratio (OR) observed for the onset of retinopathy in patients with DM and GA levels between 15.7% and 23.0%, was lower than when GA > 23.0% (OR > 8 and OR > 15, respectively), even in a statistical model adjusted for the A1C levels (17). In addition, Selvin and cols. have also demonstrated a similar association between GA and A1C regarding coronary heart disease, ischemic stroke, heart failure, and death (59).
Nathan and cols. used data from the DCCT and Epidemiology of Diabetes Interventions and Complications (EDIC) studies to evaluate the correlation between GA and chronic complications in type 1 DM. They showed that GA, as well as A1C, were strongly associated with the onset of retinopathy and nephropathy after a mean follow-up time of 6.5 years, but none evidence was seen for 7-points glucose profile. Only A1C was associated with cardiovascular disease (16). In another smaller study with 154 type 1 DM patients followed over 2.8 years, the progression to nephropathy was associated only with GA and not with A1C. The authors did not find association between these two glycemic markers and the cardiovascular outcomes (58).
Apparently, GA is predictive for microvascular complications both in type 1 and type 2 DM. However, regarding macrovascular outcomes, GA seems to be a good marker only in type 2 DM. The mechanisms involved in the development of atherosclerosis and cardiovascular diseases in type 1 DM might explain these findings.
LIMITATIONS OF GA
Some situations that interfere with albumin metabolism may also influence GA values. Theoretically, GA is not altered by the serum albumin levels, since its values are corrected for the total albumin, but low levels of this protein are associated with increased glycation rates. On the other hand, increased protein metabolism implicates in lower GA levels (60). Therefore, in conditions as hyperthyroidism, hypothyroidism, liver cirrhosis, nephrotic syndrome with massive proteinuria, or other specific disorders, the use of GA may be misleading and should be avoided (32). However, because this test is relatively new, few studies have been carried out to verify interfering factors in GA levels.
Other interfering situations on GA levels already described are age, obesity and inflammatory conditions
(observed by the increase of C-reactive protein), smoking, and hypertriglyceridemia (11,32,37). There is little evidence regarding the interpretation of GA in different ethnic groups. However, Selvin and cols. analyzed 1,376 persons without DM and 343 with DM, and found that both GA and A1C are significantly elevated in Blacks compared to Whites (8). Thus, the data presented here show the necessity of being careful when interpreting GA levels in some clinical situations.
CONCLUSIONS
GA is a short-term marker of glycemia that has been evaluated as an alternative test to A1C in patients with DM. If compared to A1C, GA is more reliable to evaluate glycemic variability. Also, it is especially indicated for patients on hemodialysis and its levels are not affected in the presence of anemias or hemolytic processes. Compared to the fructosamine test, GA is more advantageous, since it is not influenced by other serum proteins. The enzymatic methodology for its analysis is easy and quick to implement, and highly efficient analytically and with greater standardization. As previously described, in clinical situations that falsely alter A1C levels, the measurement of GA may assign a reliable result for monitoring DM. However, the physiology of the formation of these two glycated proteins ensures advantages to GA compared to A1C in access glucose control, even in the absence of interfering factors. Finally, many studies have shown that GA has good diagnostic accuracy and is strongly associated with the diabetic microvascular complications. Despite all benefits of GA, it does not replace the use of A1C, once each test has its advantages and limitations. The choice regarding which test to use should be guided by the clinical patient features and tests availability. Further, it is necessary an international consensus about laboratory issues and clinical use of GA, to guarantee its inclusion in the routine of clinical laboratory worldwide, thus improving the future screening and management of DM patients. Acknowledgments: this work was supported by Research Incen-tive Fund (FIPE) from the Hospital de Clínicas de Porto Alegre (HCPA). L.R.E. is recipient of a scholarship from Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (Fapergs). Fundings: no competing financial interests exist.
Disclosure: no potential conflict of interest relevant to this article was reported.
Cop
yright
© AE&M all rights r
eser
ved.
REFERENCES
1. International Diabetes Federation: IDF Diabetes Atlas. 7th ed. Bel-gium: International Diabetes Federation, 2015.
2. American Diabetes Association: Standards of Medical Care in Diabetes – 2016. Diabetes Care 2016;39(Supplement1):S1-S112. 3. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM,
Parrott M. Guidelines and recommendations for laboratory analy-sis in the diagnoanaly-sis and management of diabetes mellitus. Clin Chem. 2011;57(6):e1-e47.
4. The Diabetes Control and Complications Trial Research Group (DCCT). The effect of intensive treatment of diabetes on the de-velopment and progression of long-term complications in insu-lin-dependent diabetes mellitus. N Engl JMed. 1993;30;329(14): 977-86.
5. U.K. Prospective Diabetes Study (UKPDS) Group: Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or in-sulin compared with conventional treatment and risk of complica-tions in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-53. 6. Cavagnolli G, Pimentel AL, Freitas PA, Gross JL, Camargo JL.
Fac-tors affecting A1C in non-diabetic individuals: Review and meta-analysis. Clin Chim Acta. 2015;445:107-14.
7. National Glycohemoglobin Standardization Program (NGSP): fac-tors that interfere with HbA1c test results. 2015. Available from: <http://www.ngsp.org/factors.asp>. Accessed on: Dec 4, 2015. 8. Selvin E, Steffes MW, Ballantyne CM, Hoogeveen RC, Coresh
J, Brancati FL. Racial differences in glycemic markers: a cross-sectional analysis of community-based data. Ann Intern Med. 2011;154(5):303-9.
9. Ziemer DC, Kolm P, Weintraub WS, Vaccarino V, Rhee MK, Twom-bly JG, et al. Glucose-independent, black-white differences in he-moglobin A1c levels: a cross-sectional analysis of 2 studies. Ann Intern Med. 2010;152(12):770-7.
10. Kohzuma T, Koga M. Lucica GA-L glycated albumin assay kit: a new diagnostic test for diabetes mellitus. Mol Diagn Ther. 2010;14(1):49-51.
11. Koga M, Kasayama S. Clinical impact of glycated albumin as an-other glycemic control marker. Endocr J. 2010;57(9):751-62. 12. Kouzuma T, Usami T, Yamakoshi M, Takahashi M, Imamura S. An
enzymatic method for the measurement of glycated albumin in biological samples. Clin Chim Acta. 2002;324(1-2):61-71. 13. Kim C, Bullard KM, Herman WH, Beckles GL. Association between
iron deficiency and A1C Levels among adults without diabetes in the National Health and Nutrition Examination Survey, 1999-2006. Diabetes Care. 2010;33(4):780-5.
14. Freedman BI, Shenoy RN, Planer JA, Clay KD, Shihabi ZK, Burkart JM, et al. Comparison of glycated albumin and hemoglobin A1c concentrations in diabetic subjects on peritoneal and hemodialy-sis. Perit Dial Int. 2010;30(1):72-9.
15. Sany D, Elshahawy Y, Anwar W. Glycated albumin versus glycated hemoglobin as glycemic indicator in hemodialysis patients with diabetes mellitus: variables that influence. Saudi J Kidnei Dis Transpl. 2013;24(2):260-73.
16. Nathan DM, McGee P, Steffes MW, Lachin JM; DCCT/EDIC Re-search Group. Relationship of glycated albumin to blood glu-cose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study. Diabetes. 2014;63(1):282-90.
17. Selvin E, Rawlings AM, Grams M, Klein R, Sharrett AR, Steffes M, et al. Fructosamine and glycated albumin for risk stratifica-tion and predicstratifica-tion of incident diabetes and microvascular com-plications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol. 2014;2(4):279-88.
18. Anguizola J, Matsuda R, Barnaby OS, Hoy KS, Wa C, DeBolt E, et al. Glycation of human serum albumin. Clin Chim Acta. 2013;425:64-76.
19. Danese E, Montagnana M, Nouvenne A, Lippi G. Advantages and pitfalls of fructosamine and glycated albumin in the diagnosis and treatment of diabetes. J Diabetes Sci Technol. 2015;9(2):169-76. 20. Ueda Y, Matsumoto H. Recent topics in chemical and clinical research
on glycated albumin. J Diabetes Sci Technol. 2015;9(2):177-82. 21. Arasteh A, Farahi S, Habibi-Rezaei M, Moosavi-Movahedi AA.
Glycated albumin: an overview of the In Vitro models of an In Vivo potential disease marker. J Diabetes Metab Disord. 2014;13:49. 22. Cohen MP. Intervention strategies to prevent pathogenetic effects
of glycated albumin. Arch Biochem Biophys. 2003;419(1):25-30. 23. Garlick RL, Mazer JS. The principal site of nonenzymatic
gly-cosylation of human serum albumin in vivo. J Biol Chem. 1983;258:6142-6.
24. Kisugi R, Kouzuma T, Yamamoto T, Akizuki S, Miyamoto H, Someya Y, et al. Structural and glycation site changes of albumin in dia-betic patient with very high glycated albumin. Clin Chim Acta. 2007;382(1-2):59-64.
25. Rondeau P, Bourdon E. The glycation of albumin: structural and functional impacts. Biochimie. 2011;93(4):645-58.
26. Khan MS, Tabrez S, Rabbani N, Shah A. Oxidative Stress Medi-ated Cytotoxicity of GlycMedi-ated Albumin: Comparative Analysis of Glycation by Glucose Metabolites. J Fluoresc. 2015;25(6):1721-6. 27. Singh VP, Bali A, Singh N, Jaggi AS. Advanced Glycation End
Products and Diabetic Complications. Korean J Physiol Pharma-col. 2014;18(1):1-14.
28. Raghav A, Ahmad J. Glycated serum albumin: a potential disease marker and an intermediate index of diabetes control. Diabetes Metab Syndr. 2014;8(4):245-51.
29. Roohk HV, Zaidi AR. A review of glycated albumin as an inter-mediate glycation index for controlling diabetes. J Diabetes Sci Technol. 2008;2(6):1114-21.
30. Paroni R, Ceriotti F, Galanello R, Battista Leoni G, Panico A, Scu-rati E, et al. Performance characteristics and clinical utility of an enzymatic method for the measurement of glycated albumin in plasma. Clin Biochem. 2007;40(18):1398-405.
31. Kohzuma T, Yamamoto T, Uematsu Y, Shihabi ZK, Freedman BI. Basic Performance of an Enzymatic Method for Glycated Albu-min and Reference Range DeterAlbu-mination. J Diabetes Sci Technol. 2011;5(6):1455-62.
32. Furusyo N, Hayashi J. Glycated albumin and diabetes mellitus. Biochim Biophys Acta. 2013;1830(12):5509-14.
33. Rodriguez-Capote K, Tovell K, Holmes D, Dayton J, Higgins TN. Analytical evaluation of the Diazyme glycated serum protein as-say on the siemens ADVIA 1800: comparison of results against HbA1c for diagnosis and management of diabetes. J Diabetes Sci Technol. 2015;9(2):192-9.
34. Freitas PAC, Ehlert LR, Camargo JL. Comparison between two enzymatic methods for glycated albumin. Anal Methods. 2016;8:8173-8.
35. Montagnana M, Paleari R, Danese E, Salvagno GL, Lippi G, Guidi GC, et al. Evaluation of biological variation of glycated albu-min (GA) and fructosaalbu-mine in healthy subjects. Clin Chim Acta. 2013;423:1-4.
36. Watano T, Sasaki K, Omoto K, Kawano M. Stability of stored samples for assays of glycated albumin. Diabetes Res Clin Pract. 2013;101(1):e1-2.
37. Koga M. Glycated albumin; clinical usefulness. Clin Chim Acta. 2014;433:96-104.
38. Silva JF, Pimentel AL, Camargo JL. Effect of iron deficiency anae-mia on HbA1c levels is dependent on the degree of anaeanae-mia. Clin Biochem. 2016;49(1):117-20.
Cop
yright
© AE&M all rights r
eser
ved.
39. Suzuki S, Koga M, Amamiya S, Nakao A, Wada K, Okuhara K, et al. Glycated albumin but not HbA1c reflects glycaemic control in patients with neonatal diabetes mellitus. Diabetologia. 2011;54(9):2247-53. 40. Hashimoto K, Koga M. Indicators of glycemic control in patients
with gestational diabetes mellitus and pregnant women with dia-betes mellitus. World J Diadia-betes. 2015;6(8):1045-56.
41. Hashimoto K, Osugi T, Noguchi S, Morimoto Y, Wasada K, Imai S, et al. A1C but not serum glycated albumin is elevated because of iron deficiency in late pregnancy in diabetic women. Diabetes Care. 2010;33(3):509-11.
42. Zheng CM, Ma WY, Wu CC, Lu KC. Glycated albumin in diabetic patients with chronic kidney disease. Clin Chim Acta. 2012;413(19-20):1555-61.
43. Vos FE, Schollum JB, Walker RJ. Glycated albumin is the preferred marker for assessing glycaemic control in advanced chronic kid-ney disease. NDT Plus. 2011;4(6):368-75.
44. Harada K, Sumida K, Yamaguchi Y, Akai Y. Relationship between the accuracy of glycemic markers and the chronic kidney disease stage in patients with type 2 diabetes mellitus. Clin Nephrol. 2014;82(2):107-14.
45. Carson AP, Reynolds K, Fonseca VA, Muntner P. Comparison of A1c and fasting glucose criteria to diagnose diabetes among US adults. Diabetes Care. 2010;33(1):95-7.
46. Cavagnolli G, Comerlato J, Comerlato C, Renz PB, Gross JL, Ca-margo JL. HbA1c measurement for the diagnosis of diabetes: is it enough? Diabet Med. 2011;28(1):31-5.
47. Tominaga M, Makino E, Yoshino G, et al.: Report of the committee on standardization of laboratory testing related to diabetes mel-litus of Japan Diabetes Society: determination of reference inter-vals of hemoglobin A1c (IFCC) and glycoalbumin in the Japanese population. J Japan Diab Soc. 2006;49:825-33.
48. Furusyo N, Koga T, Ai M, Otokozawa S, Kohzuma T, Ikezaki H, et al. Utility of glycated albumin for the diagnosis of diabetes mellitus in a Japanese population study: results from the Kyushu and Oki-nawa Population Study (KOPS). Diabetologia. 2011;54(12):3028-36. 49. Ikezaki H, Furusyo N, Ihara T, Hayashi T, Ura K, Hiramine S, et al. Glycated albumin as a diagnostic tool for diabetes in a general Japanese population. Metabolism. 2015;64(6):698-705.
50. Hwang YC, Jung CH, Ahn HY, Jeon WS, Jin SM, Woo JT, et al. Opti-mal glycated albumin cutoff value to diagnose diabetes in Korean
adults: a retrospective study based on the oral glucose tolerance test. Clin Chim Acta. 2014;437:1-5.
51. Hsu P, Ai M, Kanda E, Yu NC, Chen HL, Chen HW, et al. A com-parison of glycated albumin and glycosylated hemoglobin for the screening of diabetes mellitus in Taiwan. Atherosclerosis. 2015;242(1):327-33.
52. Sumner AE, Duong MT, Aldana PC, Ricks M, Tulloch-Reid MK, Lozier JN, et al. A1C Combined With Glycated Albumin Improves Detection of Prediabetes in Africans: The Africans in America Study. Diabetes Care. 2016;39(2):271-7.
53. Testa R, Ceriotti F, Guerra E, Bonfigli AR, Boemi M, Cucchi M, et al. Glycated albumin: correlation to HbA1c and preliminary refer-ence interval evaluation. Clin Chem Lab Med. 2017;55(2):e31-e33. 54. Chan CL, Pyle L, Kelsey M, Newnes L, Zeitler PS, Nadeau KJ. Screening for type 2 diabetes and prediabetes in obese youth: evaluating alternate markers of glycemia - 1,5-anhydrogluci-tol, fructosamine, and glycated albumin. Pediatric Diabetes. 2016;17(3):206-11.
55. Yoshiuchi K, Matsuhisa M, Katakami N, Nakatani Y, Sakamoto K, Matsuoka T, et al. Glycated albumin is a better indicator for glu-cose excursion than glycated hemoglobin in type 1 and type 2 diabetes. Endocr J. 2008;55(3):503-7.
56. Yoon HJ, Lee YH, Kim KJ, Kim SR, Kang ES, Cha BS, et al. Gly-cated Albumin Levels in Patients with Type 2 Diabetes Increase Relative to HbA1c with Time. Biomed Res Int. 2015;2015:1-8. 57. Suwa T1, Ohta A, Matsui T, Koganei R, Kato H, Kawata T, et al.
Rela-tionship between clinical markers of glycemia and glucose excur-sion evaluated by continuous glucose monitoring (CGM). Endocr J. 2010;57(2):135-40.
58. Yoon HJ, Lee YH, Kim SR, Rim TH, Lee EY, Kang ES, et al. Glycated albumin and the risk of micro- and macrovascular complications in subjects with Type 1 Diabetes. Cardiovasc Diabetol. 2015;14:53. 59. Selvin E, Rawlings AM, Lutsey PL, Maruthur N, Pankow JS, Steffes M, et al. Fructosamine and Glycated Albumin and the Risk of Car-diovascular Outcomes and Death. Circulation. 2015;132(4):269-77. 60. Bhonsle HS, Korwar AM, Kote SS, Golegaonkar SB, Chougale AD, Shaik ML, et al. Low plasma albumin levels are associated with increased plasma protein glycation and HbA1c in diabetes. J Pro-teome Res. 2012;11(2):1391-6.
